Literature DB >> 559229

Combination therapy for osteoporosis.

J F Aloia, I Zanzi, A Vaswani, K Ellis, S H Cohn.   

Abstract

The effect of therapy that simultaneously stimulates bone formation and inhibits bone resporption was evaluated in five patients with primary osteoporosis. The technique of in vivo neutron activation analysis was used to measure total body calcium (TB-Ca). The patients were treated with calcium supplements and salmon calcitonin combined with either a low or a high dose of growth hormond (hGH). There was no significant increase in skeletal mass (TB-Ca) during the low-dose hGH regimen. An increase in skeletal mass was observed in all patients following the high-dose regimen, except for one patient who developed secondary hyperparathyroidism. Although this study must be considered to be of a preliminary nature, the magnitude of the response in calcium balance suggests that skeletal mass can be increased in osteoporosis if combination therapy is employed.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 559229     DOI: 10.1016/0026-0495(77)90066-x

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  4 in total

Review 1.  Combination therapy for osteoporosis: considerations and controversy.

Authors:  Neil Binkley; Diane Krueger
Journal:  Curr Rheumatol Rep       Date:  2005-03       Impact factor: 4.592

Review 2.  Combination therapy for osteoporosis: considerations and controversy.

Authors:  Neil Binkley; Diane Krueger
Journal:  Curr Osteoporos Rep       Date:  2005-12       Impact factor: 5.096

3.  Coherence treatment of postmenopausal osteoporosis with growth hormone and calcitonin.

Authors:  J F Aloia; A Vaswani; P J Meunier; C M Edouard; M E Arlot; J K Yeh; S H Cohn
Journal:  Calcif Tissue Int       Date:  1987-05       Impact factor: 4.333

4.  Human growth hormone and growth hormone releasing hormone: a double-masked, placebo-controlled study of their effects on bone metabolism in elderly women.

Authors:  B Clemmesen; K Overgaard; B Riis; C Christiansen
Journal:  Osteoporos Int       Date:  1993-12       Impact factor: 4.507

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.